Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT07062952

Kidney-protective Intervention With Salt Substitute After Kidney Tumor Surgery

Led by Jinling Hospital, China · Updated on 2025-12-15

200

Participants Needed

1

Research Sites

140 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This clinical trial is an open-label, randomized controlled study designed to evaluate the efficacyand safety of salt substitutes in protecting renal function after kidney tumor surgery, aiming toprovide dietary renal protection strategies for postoperative kidney tumor patients. lt will alsoassess the feasibility of salt substitute intervention. The primary research questions are: 1. Does a salt substitute diet significantly improve estimated glomerular filtration rate (eGFR) compared to a regular salt diet in postoperative kidney tumor patients? 2. What is the safety profile of salt substitute intervention in postoperative kidney tumor patients? 3. What is the compliance rate among postoperative kidney tumor patients using saltsubstitutes? 4. ls the salt substitute intervention feasible? Researchers will compare the intervention group (salt substitute diet) with the control group (regular salt diet) to determine whether salt substitutes effectively improve postoperative eGFR in kidney tumor patients. Participants will be required to: 1. Consume salt substitutes or regular salt daily while strictly adhering to WHO-recommendedsalt intake levels for 1 year. 2. Undergo scheduled baseline assessments at 1, 3, 6, and 12 months post-surgery, with 24-hoururine tests at months 1 and 6 to evaluate compliance. 3. Receive regular monitoring of blood electrolytes, eGFR, and other renal function indicators. 4. Document any adverse events or health status changes during the study period.

CONDITIONS

Official Title

Kidney-protective Intervention With Salt Substitute After Kidney Tumor Surgery

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Voluntary participation with signed informed consent from the participant and cohabiting family members, with commitment to study procedures and follow-up
  • Age 18 years or older at enrollment
  • Diagnosed with kidney tumor and underwent radical or partial nephrectomy
  • Preoperative estimated glomerular filtration rate (eGFR) greater than 60 ml/min/1.73m²
  • Serum potassium level below 4.8 mmol/L
  • Predominantly home-based dietary habits with more than 90% of meals prepared at home
  • Normal function of the opposite kidney at screening
  • Normal heart, lung, and liver function
Not Eligible

You will not qualify if you...

  • Currently using potassium-sparing diuretics, potassium supplements, or prior use of salt substitutes by participant or cohabiting family members
  • Post-discharge eGFR less than 45 ml/min/1.73m² without significant fluctuation
  • Presence of chronic kidney diseases such as diabetic nephropathy or lupus nephritis
  • History of urinary tract obstruction before surgery
  • Cohabiting family members with chronic kidney disease (eGFR less than 45 ml/min/1.73m²)
  • Planned use of nephrotoxic medications after surgery including anti-neoplastic agents or immunotherapy
  • Uncontrolled diabetes with HbA1c 12% or higher
  • Uncontrolled high blood pressure (seated systolic BP 180 mmHg or higher, or diastolic BP 110 mmHg or higher), symptomatic low blood pressure (systolic BP below 90 mmHg), or clear signs of low blood volume
  • Preoperative proteinuria of 1+ or more on dipstick test
  • Severe heart disease (NYHA Class III-IV), gastrointestinal blockage, or history of high potassium levels
  • Body mass index (BMI) below 18.5 kg/m² or above 30 kg/m²
  • Participation in another clinical trial within 30 days before randomization or during this study
  • Communication difficulties or expected inability to follow study procedures
  • Structural or functional urinary tract abnormalities or use of indwelling catheters
  • Previous radiotherapy, ablation, or surgery on the opposite kidney
  • Life expectancy less than 6 months due to conditions like metastatic kidney cancer

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing

Nanjing, Jiangsu, China, 210000

Actively Recruiting

Loading map...

Research Team

Q

Qu Le M.D

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here